Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18264379 | 0.88 | KMO (0.50) | KMOTSHRKMT2AUSP2HTT | |
| SCHEMBL18264332 | 0.81 | KMO (0.43) | KMOTSHRKMT2AUSP2HTT | |
| SCHEMBL16897914 | 0.79 | TSHR (0.69) | TSHRKMT2AHTTCYP3A4CYP2C19 | |
| SCHEMBL31444652 | 0.78 | TSHR (0.46) | KMOTSHRKMT2ACYP3A4CYP2C19 | |
| SCHEMBL18272478 | 0.77 | KMO (0.49) | KMOTSHRKMT2AUSP2HTT | |
| SCHEMBL18264345 | 0.77 | KMO (0.43) | KMOTSHRKMT2AUSP2HTT | |
| SCHEMBL7268703 | 0.75 | KMO (0.51) | KMOTSHRKMT2AUSP2HTT | |
| SCHEMBL31444551 | 0.74 | MAPT (0.46) | KMOTSHRKMT2ACYP3A4CYP2C19 | |
| SCHEMBL5799939 | 0.74 | KMT2A (0.47) | KMOTSHRKMT2ACYP3A4CYP2C19 | |
| SCHEMBL18264343 | 0.74 | KMO (0.54) | KMOTSHRKMT2AUSP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611756-B2 | Method of treating pancreatitis using 1,4-benzoxazine derivatives | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2020-04-07 | — | — | US | disclosed |
| US-10611756-B2 | Method of treating pancreatitis using 1,4-benzoxazine derivatives | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20190169178-A1 | METHODS | DR. FALK PHARMA GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169178-A1 | METHODS | DR. FALK PHARMA GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-10246447-B2 | 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-02 | — | — | US | disclosed |
| US-10246447-B2 | 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-02 | — | — | US | disclosed |
| US-20180170920-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | DR. FALK PHARMA GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180170920-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | DR. FALK PHARMA GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180170920-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | DR. FALK PHARMA GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| EP-3298009-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016188827-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016188827-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611756-B2 | Method of treating pancreatitis using 1,4-benzoxazine derivatives | AMY2A, KMO, KLK5 | KMO 2/4885TSHR 2621/4885KMT2A 490/4885 |
| US-10246447-B2 | 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors | KMO, SNCA, AP1S1 | KMO 1/4885TSHR 1898/4885KMT2A 1829/4885 |
| US-20180170920-A1 | 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS | KMO, SNCA, AP1S1 | KMO 1/4885TSHR 1898/4885KMT2A 1829/4885 |
| US-20190169178-A1 | METHODS | KMO, AMY2A, RNASE1 | KMO 1/4885TSHR 3252/4885KMT2A 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.